Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2020-05-12 Proxy Solicitation & In…
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2020-05-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2020, reporting the company's financial results for the quarter ended March 31, 2020. It includes a press release as an exhibit announcing the quarterly financial results. The document is relatively short (3958 characters) and primarily serves as a current report to announce earnings results rather than providing detailed financial statements or comprehensive analysis. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Therefore, the appropriate classification is ER with high confidence.
2020-05-12 English
10-Q
Interim / Quarterly Report Q1 2020
2020-05-11 English
FORM 10-K/A
Annual Report FY 2019
2020-04-29 English
FORM 4/A SUBMISSION
Director's Dealing
2020-03-24 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions an announcement of positive top-line results from a Phase 3 clinical trial and references an attached press release and investor presentation. The document does not contain detailed financial statements or comprehensive financial analysis itself but rather provides an update and references exhibits including a press release and an investor presentation. The presence of an investor presentation as an exhibit and the nature of the announcement indicate this filing is primarily an update on company developments and investor communication rather than a full financial report or earnings release. Therefore, the most appropriate classification is Investor Presentation (IP).
2020-03-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.